Current Liabilities
Accounts Payable
Pfizer Accounts Payable decreased by 14.0% to $4.51B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 14.0%, from $5.24B to $4.51B. Over 5 years (FY 2020 to FY 2025), Accounts Payable shows an upward trend with a 4.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
Increasing accounts payable can be a source of interest-free financing, but excessive delays in payment may signal liquidity issues or strained supplier relationships.
Detailed definition
Accounts payable represents the total amount owed to suppliers and vendors for goods and services received on credit. It...
Peer comparison
Often compared via the 'Days Payable Outstanding' metric to assess payment efficiency against industry peers.
Metric ID:
accounts_payableHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.33B | $4.70B | $5.58B | $5.51B | $6.21B | $6.27B | $6.81B | $6.12B | $6.08B | $5.34B | $6.71B | $5.59B | $5.11B | $5.31B | $5.63B | $5.24B | $5.17B | $5.02B | $5.24B | $4.51B |
| QoQ Change | — | +8.6% | +18.7% | -1.3% | +12.7% | +1.0% | +8.6% | -10.1% | -0.7% | -12.2% | +25.7% | -16.7% | -8.7% | +4.1% | +6.0% | -7.0% | -1.4% | -2.7% | +4.3% | -14.0% |
| YoY Change | — | — | — | — | +43.5% | +33.4% | +22.1% | +11.2% | -2.0% | -14.8% | -1.5% | -8.7% | -16.0% | -0.4% | -16.1% | -6.3% | +1.2% | -5.5% | -7.0% | -14.0% |
Range$4.33B – $6.81B
CAGR+0.9%
Avg YoY Growth+1.2%
Median YoY Growth-3.8%
Accounts Payable at Other Companies
Frequently Asked Questions
- What is Pfizer's accounts payable?
- Pfizer (PFE) reported accounts payable of $4.51B in Q1 2026.
- How has Pfizer's accounts payable changed year-over-year?
- Pfizer's accounts payable decreased by 14.0% year-over-year, from $5.24B to $4.51B.
- What is the long-term trend for Pfizer's accounts payable?
- Over 5 years (2020 to 2025), Pfizer's accounts payable has grown at a 4.1% compound annual growth rate (CAGR), from $4.28B to $5.24B.
- What does accounts payable mean?
- Money the company owes to its suppliers.